Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Utilizing Liver-Directed Therapies in Pancreatic NETs

July 28th 2015

Targeted Therapies in Pancreatic Neuroendocrine Tumors

July 28th 2015

Chemotherapy in Poorly Differentiated pNETs

July 28th 2015

Using Somatostatin Analogs in pNETs

July 28th 2015

Somatostatin Analogs in Pancreatic Neuroendocrine Tumors

July 28th 2015

Surgical Intervention in Pancreatic NETs

July 28th 2015

Newly Diagnosed Pancreatic Neuroendocrine Tumors

July 28th 2015

Introduction: Biology of Pancreatic Neuroendocrine Tumors

July 28th 2015

Dr. Arber on Aspirin for Colorectal Cancer Prevention

July 27th 2015

Nadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.

Dr. Luis A. Diaz, Jr. on Pembrolizumab For MMR-Deficient Colorectal Cancer

July 23rd 2015

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).

Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

July 16th 2015

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

MM-398 and Other Novel Agents Improve Outlook in Pancreatic Cancer

July 16th 2015

Philip Philip, MD, PhD, discusses how MM-398 and other emerging therapies are offering new hope to patients with pancreatic cancer.

Global Perspective on the ASCO Annual Meeting

July 16th 2015

New Agents for Refractory Metastatic Colorectal Cancer

July 16th 2015

Immunotherapy in Colorectal Cancer

July 16th 2015

Maintenance Therapy in Colorectal Cancer

July 16th 2015

EGFR Inhibition in RAS Wild-Type Unresectable mCRC

July 16th 2015

Daily Aspirin for Colorectal Cancer Prevention

July 16th 2015

Impact of the SIRFLOX Study on CRC Management

July 16th 2015

Role of Surgery in Metastatic Colorectal Cancer

July 16th 2015